In conclusion, our data demonstrated that sunitinib-resistant ccRCC cell lines aberrantly expressed PD-L1 and presented an increased activation of the Axl and MAPK pathways, and a metabolic shift toward oxidative phosphorylation and glutamine metabolism. Here, AXL is linked to nonpapillary renal cell carcinoma.